Prescient Therapeutics (ASX:PTX) FCF Margin % : 0.00% (As of Dec. 2023)

View and export this data going back to 1986. Start your Free Trial

What is Prescient Therapeutics FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Prescient Therapeutics's Free Cash Flow for the six months ended in Dec. 2023 was A$-3.49 Mil. Prescient Therapeutics's Revenue for the six months ended in Dec. 2023 was A$0.00 Mil. Therefore, Prescient Therapeutics's FCF Margin % for the quarter that ended in Dec. 2023 was 0.00%.

As of today, Prescient Therapeutics's current FCF Yield % is -16.42%.

The historical rank and industry rank for Prescient Therapeutics's FCF Margin % or its related term are showing as below:

During the past 13 years, the highest FCF Margin % of Prescient Therapeutics was -14181.82%. The lowest was -14181.82%. And the median was -14181.82%.

ASX:PTX's FCF Margin % is not ranked ^*
in the Biotechnology industry.
Industry Median: -148.24
* Ranked among companies with meaningful FCF Margin % only.

Prescient Therapeutics FCF Margin % Historical Data

The historical data trend for Prescient Therapeutics's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Prescient Therapeutics FCF Margin % Chart

Prescient Therapeutics Annual Data

Trend

Jun13

Jun14

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

FCF Margin %

Get a 7-Day Free Trial

Prescient Therapeutics Semi-Annual Data
	Dec13	Jun14	Dec14	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
FCF Margin %	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Prescient Therapeutics's FCF Margin %

For the Biotechnology subindustry, Prescient Therapeutics's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Prescient Therapeutics's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Prescient Therapeutics's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Prescient Therapeutics's FCF Margin % falls into.

Prescient Therapeutics FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Prescient Therapeutics's FCF Margin for the fiscal year that ended in Jun. 2023 is calculated as

FCF Margin	=	Free Cash Flow (A: Jun. 2023 )	/	Revenue (A: Jun. 2023 )
	=	-6.191	/	0
	=	%

Prescient Therapeutics's FCF Margin for the quarter that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (Q: Dec. 2023 )	/	Revenue (Q: Dec. 2023 )
	=	-3.485	/	0
	=	%

Prescient Therapeutics FCF Margin % Related Terms

Thank you for viewing the detailed overview of Prescient Therapeutics's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Prescient Therapeutics (ASX:PTX) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Prescient Therapeutics Ltd (ASX:PTX) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

N/A

Address

Level 4, 100 Albert Road, South Melbourne, Melbourne, VIC, AUS, 3205

Website

https://www.ptxtherapeutics.com

Prescient Therapeutics Ltd is a clinical-stage oncology company. The company develops novel compounds for the treatment of a range of cancers in Australia. Its product in the pipeline includes OmniCAR; PTX-100 and PTX-200. OmniCAR is a universal immune receptor platform enabling controllable T-cell activity and multi-antigen targeting with a single cell product.

Prescient Therapeutics (ASX:PTX) Headlines

No Headlines